Use the interactive map to see where our network members can support your employees Our local member insurers provide wellness resources and programmes for your subsidiaries Tailored solutions designed to help multinational employers manage their global employee benefits (EB) Helping employers gain control and flexibility over their employee benefits Enabling employers to maximise global economies of scale for an efficient approach to insuring EB Providing employers with consolidated financial data to help them understand their EB risks Our two-step approach to wellness helps you understand your employee health data and tackle your biggest cost drivers See a standardised view of your local medical spend in over 50 countries with our suite of reports and dashboards Wellness educational campaigns designed to help you implement awareness and education programmes Our marketplace of partners can deliver global wellness programmes to your employees Your enhanced suite of health data insights and wellness services See our latest news, upcoming events and a library full of our latest articles, whitepapers, podcast episodes and more Read our latest news and articles We host and participate in regular events around the world, discussing all things EB Our monthly Viewpoint articles tackle the biggest topics in the world of global EB Our whitepapers provide a deeper perspective on health and wellness issues and other EB challenges Listen to the MAXIS team sharing their EB insights Watch our latest videos Rewatch our webinars Download our corporate literature, all in one place Find out more about MAXIS, our people and how we help multinational employers solve their global employee benefits challenges We're the leading global employee benefits network, working with more than 300 multinational clients Accountability, Collaboration and Creativity - our values drive our people and help us provide the best service possible to multinationals Meet our Executive Committee Working to make a positive impact through everything we do See our latest vacancies and find out what makes MAXIS a great place to work Copyright 2026 MAXIS GBN
Participants in the study discontinued treatment within 3 to 12 months, and researchers tracked their weight changes and subsequent treatments for one year after stopping the medication
Lymphadenoid goitre and the syndrome of systemic lupus erythematosus
You can edit or delete your press release GLP-1 Market Key Players Analysis - AstraZeneca, Biolingus, Boehringer Ingelheim, D&D Pharmatech
Why patients in White Plains choose GoalBMI Wellness Fully online process Start and continue care from home no clinic visits required
If macroprolactinemia is suspected, the laboratory should be notified, and the specimen can be subjected to polyethylene glycol precipitation before assessment.3 If macroprolactinemia accounts for most of the prolactin excess, no specific treatment is needed
